CRISPR Therapeutics has transitioned from a commercial-stage launch to a development-stage model, with TTM revenue collapsing to $3.5M (a 90% YoY decline) and gross margins deeply negative at -6,537% TTM, indicating that CASGEVY's initial revenue has faded whi...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue collapsed to $10.2M in 2026Q2 (a 90% YoY decline from the $35M peak in 2024Q4), with gross margin at -3.4% and operating margin at -11.3%, reflecting fixed manufacturing costs far ahead of commercial sales.
Q2 2026 CASGEVY revenue acceleration above $5M confirms strong commercial uptake and growth potential.
Upcoming H2 2026 cardiovascular data for CTX310 could validate the multi-platform thesis and trigger a significant stock re-rating.
ARK Investment Management increased its stake, reflecting growing confidence from large investors in CRISPR's pipeline.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.94+21.0% vs -$1.19 | $10M+36.7% vs $7M |
Q2 2026 May 4, 2026 | -$1.28-7.6% vs -$1.19 | $1M-76.0% vs $6M |
Q1 2026 Feb 12, 2026 | -$1.37-19.1% vs -$1.15 | $864,000-81.7% vs $5M |
Q4 2025 Nov 10, 2025 | -$1.17+7.1% vs -$1.26 | $889,000-90.3% vs $9M |
Even if it's not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year. That being said, CRISPR Therapeutics' developmental pipeline shows promise well beyond Casgevy's potential.
CRISPR Therapeutics will likely be a much larger company in 10 years. Much of that time will be spent refining the technologies it already has in hand today.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -2.19% change compared to its last close.
Benchmark CRSP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CRISPR Therapeutics AG (CRSP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $59.03 | $5.69B | -9.12 | -89.97% | -16569.77% | -30.18% | — | |
| $2.92 | $448.11M | -1.62 | 25.39% | -157.32% | -196.63% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — | |
| $3.54 | $639.39M | -2.62 | 55.28% | -4613.11% | -188.27% | — |
CRISPR Therapeutics AG (CRSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CRISPR Therapeutics AG (CRSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 4, 2026·SEC
May 4, 2026·SEC
Get notified when CRSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRISPR Therapeutics AG (CRSP) stock FAQ — growth, dividends, profitability & financials explained
CRISPR Therapeutics AG (CRSP) reported $13.4M in revenue for fiscal year 2025.
CRISPR Therapeutics AG (CRSP) saw revenue decline by 90.0% over the past year.
CRISPR Therapeutics AG (CRSP) reported a net loss of $451.1M for fiscal year 2025.
CRISPR Therapeutics AG (CRSP) has a return on equity (ROE) of -30.2%. Negative ROE indicates the company is unprofitable.
CRISPR Therapeutics AG (CRSP) had negative free cash flow of $480.7M in fiscal year 2025, likely due to heavy capital investments.
